ES2549690A2 - Inmunoterapéuticos polivalentes de alta especificidad basados en anticuerpos modificados y formulación liofilizada inyectable altamente segura y eficaz - Google Patents

Inmunoterapéuticos polivalentes de alta especificidad basados en anticuerpos modificados y formulación liofilizada inyectable altamente segura y eficaz Download PDF

Info

Publication number
ES2549690A2
ES2549690A2 ES201300887A ES201300887A ES2549690A2 ES 2549690 A2 ES2549690 A2 ES 2549690A2 ES 201300887 A ES201300887 A ES 201300887A ES 201300887 A ES201300887 A ES 201300887A ES 2549690 A2 ES2549690 A2 ES 2549690A2
Authority
ES
Spain
Prior art keywords
injectable formulation
high specificity
modified antibodies
immunotherapeutics
polyvalent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES201300887A
Other languages
English (en)
Other versions
ES2549690B1 (es
ES2549690B8 (es
ES2549690R1 (es
Inventor
Juan LÓPEZ DE SILANES PÉREZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
INOSAN BIOPHARMA S A
Inosan Biopharma Sa
Original Assignee
INOSAN BIOPHARMA S A
Inosan Biopharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INOSAN BIOPHARMA S A, Inosan Biopharma Sa filed Critical INOSAN BIOPHARMA S A
Publication of ES2549690A2 publication Critical patent/ES2549690A2/es
Publication of ES2549690R1 publication Critical patent/ES2549690R1/es
Publication of ES2549690B1 publication Critical patent/ES2549690B1/es
Application granted granted Critical
Publication of ES2549690B8 publication Critical patent/ES2549690B8/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Inmunoterapéuticos polivalentes de alta especificidad basados en anticuerpos modificados y formulación liofilizada inyectable altamente segura y eficaz. La invención se relaciona con la producción y desarrollo de una formulación inyectable liofilizada de anticuerpos modificados o variantes de ellos, altamente específicos neutralizantes de mezclas heterólogas de proteínas, péptidos y otros componentes orgánicos e inorgánicos que tienen diferentes actividades específicas y pueden incluir pero no se limitan a venenos de animales ponzoñosos. Por conveniencia haremos referencia a venenos, pero se incluyen todo tipo de venenos de animales terrestres y marinos. También está dirigida al método de producción que incluye la hiperinmunización de mamíferos para la producción de anticuerpos altamente específicos, el proceso de modificación (fragmentación) y purificación, y finalmente la formulación inyectable liofilizada, que le confiere propiedades de alta pureza y alta especificidad.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6

Claims (1)

  1. imagen1
    imagen2
ES201300887A 2012-10-18 2013-09-27 Inmunoterapéuticos polivalentes de alta especificidad basados en anticuerpos modificados y formulación liofilizada inyectable altamente segura y eficaz Active ES2549690B8 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MX/A/2012/012132 2012-10-18
MX2012012132A MX367136B (es) 2012-10-18 2012-10-18 Proceso para purificar fragmentos de anticuerpos polivalentes derivados de plasma hiperinmune.

Publications (4)

Publication Number Publication Date
ES2549690A2 true ES2549690A2 (es) 2015-10-30
ES2549690R1 ES2549690R1 (es) 2016-01-11
ES2549690B1 ES2549690B1 (es) 2016-09-21
ES2549690B8 ES2549690B8 (es) 2018-06-21

Family

ID=50097480

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201300887A Active ES2549690B8 (es) 2012-10-18 2013-09-27 Inmunoterapéuticos polivalentes de alta especificidad basados en anticuerpos modificados y formulación liofilizada inyectable altamente segura y eficaz

Country Status (4)

Country Link
US (2) US10538577B2 (es)
ES (1) ES2549690B8 (es)
FR (1) FR2997084A1 (es)
MX (1) MX367136B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019070108A1 (es) 2017-10-02 2019-04-11 Laboratorios Silanes S.A. De C.V. Proceso de alto rendimiento para la producción de antivenenos de fragmentos f (ab') 2 de anticuerpos

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2065196A (en) 1934-10-09 1936-12-22 Parfentjev Ivan Alexandrovich Method for purification of antitoxins and the like
US2123198A (en) 1936-10-23 1938-07-12 Lederle Lab Inc Treatment of antitoxins and the like
US2175090A (en) 1938-06-22 1939-10-03 Lederie Lab Inc Purification of antibody compositions
US4849352A (en) 1984-10-09 1989-07-18 Sullivan John B Antibody purification process
RU2139092C1 (ru) 1993-06-03 1999-10-10 Терапьютик Антибодиз Инк. Фрагменты антител в терапии
IN188098B (es) 2000-03-09 2002-08-17 Serum Inst India Ltd
US6709655B2 (en) 2001-02-28 2004-03-23 Instituto Bioclon, S.A. De C.V. Pharmaceutical composition of F(ab1)2 antibody fragments and a process for the preparation thereof
WO2004007695A2 (en) 2002-03-08 2004-01-22 Osel, Inc. Lactobacilli expressing biologically active polypeptides and uses thereof
EP1651266B1 (en) 2003-07-25 2010-03-03 Laboratorios Silanes, S.A. de C.V. Administration of anti-tnf-alpha f(ab')2 antibody fragments
MXPA04008435A (es) 2004-08-31 2006-03-02 Univ Mexico Nacional Autonoma Inmunogeno y anti-veneno contra el veneno de la arana violinista.
MXPA06003717A (es) 2006-04-03 2006-09-29 Silanes Sa De Cv Lab Composiciones oftalmicas de proteinas inhibidoras de citocinas implicadas en procesos inflamatorios o inmunologicos.
CN101816789B (zh) 2010-04-08 2012-09-05 成都军区疾病预防控制中心军事医学研究所 抗蝰蛇蛇毒冻干血清及制备方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019070108A1 (es) 2017-10-02 2019-04-11 Laboratorios Silanes S.A. De C.V. Proceso de alto rendimiento para la producción de antivenenos de fragmentos f (ab') 2 de anticuerpos

Also Published As

Publication number Publication date
ES2549690B1 (es) 2016-09-21
US20160368969A1 (en) 2016-12-22
ES2549690B8 (es) 2018-06-21
US20200190166A1 (en) 2020-06-18
MX367136B (es) 2019-08-06
US10538577B2 (en) 2020-01-21
FR2997084A1 (fr) 2014-04-25
MX2012012132A (es) 2013-12-08
ES2549690R1 (es) 2016-01-11

Similar Documents

Publication Publication Date Title
PH12016501937A1 (en) Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage
BR112013020500A8 (pt) anticorpo isolado, recombinante ou purificado
BR112015031073A2 (pt) inibidores bicíclicos de bromodomínio
BR112017023374A2 (pt) formulação de anticorpo anti-cgrp
BR112016022841A2 (pt) cadeia j modificada
EA201590994A1 (ru) Способ увеличения гидродинамического объема полипептида путем присоединения карбоксиконцевого пептида гонадотропина
MX2017004117A (es) Moleculas de enlace, especialmente anticuerpos, enlazadas a l1cam(cd171).
EA201300137A1 (ru) Комбинированная фармацевтическая композиция и способ лечения заболеваний или состояний, связанных с нейродегенеративными зоболеваниями
BR112016014731A2 (pt) Anticorpos anti-baff
WO2014124258A3 (en) Specific sites for modifying antibodies to make immunoconjugates
BR112015022618A2 (pt) processo para a preparação de ácido levulínico
MX2020000288A (es) Cromatografia.
MX2017001516A (es) Procedimiento para producir variantes que tengan un fc con sialilacion mejorada.
BR112021025438A2 (pt) Composições de proteínas anti-vegf e métodos para produzir as mesmas
UA117493C2 (uk) Гібридна конструкція, що включає антигенсполучний фрагмент, специфічний до сироваткового альбуміну, й ефекторний компонент, та способи її одержання
BR112015018035A2 (pt) anticorpo anti-hmgb1 humanizado ou seu fragmento que se liga ao antígeno
DOP2018000128A (es) Polipéptidos que inhiben cd40l
BR112016013157A2 (pt) peptídeos resistentes à protease
MX2023009584A (es) Anticuerpos monoclonales anti-chinches y metodos de elaboracion y usos de los mismos.
BR112016030604B8 (pt) Processo para preparação de ácidos 3- hidroxipicolínicos
EA201692439A1 (ru) Пролин-специфичная эндопротеаза и ее применение
MX2016013713A (es) Procesamiento de clara de huevo.
ES2549690A2 (es) Inmunoterapéuticos polivalentes de alta especificidad basados en anticuerpos modificados y formulación liofilizada inyectable altamente segura y eficaz
WO2014122079A3 (en) Improved purification of proteins via a deglycosylation step
EA201892231A1 (ru) Способ очистки белка

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2549690

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20160921